Banco Bilbao Vizcaya Argentaria S.A. Boosts Stake in Amgen Inc. $AMGN

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Amgen by 5.8% in Q3 to 84,363 shares (worth $23.78M), and institutional ownership is high at 76.5% with other major funds (Vanguard, Capital World Investors, Norges, Charles Schwab) also adding positions.
• Earnings beat and guidance: Amgen topped estimates with $5.29 EPS (vs. $4.76) and $9.87B revenue, set FY2026 EPS guidance of 21.600–23.000, and announced a $2.52 quarterly dividend ($10.08 annual, ~2.8% yield).
• Mixed analyst view and valuation notes: Analysts' consensus is a "Hold" with an average target of $354, while the stock trades at a ~25.7 P/E and carries a high debt‑to‑equity ratio (~5.78), which some observers cite as a potential headwind.

Banco Bilbao Vizcaya Argentaria S.A. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 84,363 shares of the medical research company's stock after purchasing an additional 4,601 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Amgen were worth $23,776,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of AMGN. Laurel Wealth Advisors LLC increased its position in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company's stock worth $1,870,880,000 after buying an additional 6,676,575 shares in the last quarter. Norges Bank purchased a new position in shares of Amgen during the 2nd quarter valued at about $1,663,726,000. Capital World Investors grew its stake in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares during the period. Vanguard Group Inc. grew its stake in shares of Amgen by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company's stock valued at $14,996,807,000 after acquiring an additional 841,117 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Amgen by 5.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company's stock worth $3,600,043,000 after acquiring an additional 687,735 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on AMGN. Truist Financial raised their target price on shares of Amgen from $318.00 to $319.00 and gave the stock a "hold" rating in a research note on Thursday, January 8th. Sanford C. Bernstein lowered shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target for the company. in a research report on Tuesday, January 20th. HSBC reissued a "buy" rating and issued a $425.00 price objective on shares of Amgen in a research note on Wednesday, December 10th. Royal Bank Of Canada lifted their target price on shares of Amgen from $335.00 to $360.00 and gave the company an "outperform" rating in a research note on Wednesday, February 4th. Finally, Daiwa Securities Group upped their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $354.00.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen NASDAQ: AMGN Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis - Amgen, Inc.

Amgen Trading Down 0.4%

AMGN stock opened at $366.21 on Friday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The stock has a market capitalization of $197.41 billion, a price-to-earnings ratio of 25.74, a price-to-earnings-growth ratio of 3.63 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm's fifty day simple moving average is $357.73 and its two-hundred day simple moving average is $325.42.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the business earned $5.31 EPS. The business's revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.8%. Amgen's dividend payout ratio (DPR) is presently 70.84%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.